Irvine Scientific launches new feed media to maximize productivity in large-scale bioproduction
BalanCD CHO Feed 4 is a chemically-defined, animal component-free powder feed for large-scale bioproduction in a variety of high performing CHO cells.
Irvine Scientific has launched BalanCD CHO Feed 4, a chemically defined, animal component-free powder feed for large-scale bioproduction in a variety of high performing CHO cells. When paired with BalanCD CHO Growth A in fed-batch culture systems, up to 20 million viable cells/mL, and antibody titer up to 6g/ L can be achieved.
Recent developments in cell line engineering have resulted in cell lines capable of reaching higher cell densities and productivity rates. To achieve their full production potential these cell lines need nutrient-rich media; however these feeds can be difficult to dissolve and require complicated time-consuming preparation protocols. BalanCD CHO Feed 4 is designed and formulated to prepare easily using a simplified hydration procedure that does not require pH adjustments. BalanCD CHO Feed 4 maintains pH stability in culture and is designed to support growth while minimizing the production of metabolites that adversely affect titer levels; this results in process consistency, significantly higher protein production and protein quality.
“Surveys of large-scale culture media end-users identify time and effort required for mixing powdered media as a top concern. By applying our expertise at media development and formulation we are able to deliver a product that provides performance, flexibility and ease-of-use that facilitates a more robust process.” said Dr Jessie H.-T. Ni, Chief Scientific Officer of Irvine Scientific. “This new Feed is a significant addition to our BalanCD CHO platform that is designed to streamline the development and scale-up process to help our customers get to market faster.”
Related News
-
News Federal judge blocks Colorado's unprecedented price cap on Amgen's Enbrel
A US federal court has halted Colorado's attempt to impose a US$31,200 annual price cap on Amgen's arthritis drug Enbrel, ruling that the pharmaceutical company would likely suffer irreparable harm. The decision represents a significant blow to... -
News Protecting life-saving therapies: CPHI Online Podcast Series
The latest episode of the CPHI Podcast Series dives into a critical challenge facing the pharmaceutical industry: ensuring the integrity of temperature-sensitive medications and biologics through advanced predictive technology.
-
News 2026 Outsourcing Outlook Update - pharma at a crossroads
The pharmaceutical contract development and manufacturing organisation (CDMO) sector is experiencing unprecedented transformation, driven by evolving therapeutic complexities, geopolitical tensions, and the growing demand for specialised manufacturing ... -
News Roche maintains German investment commitment whilst rivals scale back
Pharmaceutical giant Roche has reaffirmed its commitment to investing in Germany, standing firm even as competitors Eli Lilly and Boehringer Ingelheim dramatically reduce their planned investments in response to controversial healthcare reforms.
-
News Women in Pharma: The History of CPHI Women in Japan
Our monthly Women in Pharma series highlights the influential lives and work of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive. -
News EU drafts deal to end essential medicines shortage
European negotiators have agreed new legislation to tackle persistent shortages of essential medicines by prioritising supply security over price in public procurement and supporting domestic pharmaceutical manufacturing with strategic funding.
-
News Thermo Fisher Scientific offloads microbiology business to PE firm Astorg
The life sciences giant is divesting its global microbiology unit, which generated $645 million in revenue last year, to the pan-European private equity firm as part of an active portfolio management strategy. The transaction is expected to close in th... -
News The Shift: Why Sustainability is Moving to the Centre of CPHI Milan 2026
CPHI Online contributor David Roach takes a look at how conversations around sustainability in the pharmaceutical industry can and must be transformed into actionable deliveries, and what the inaugural CPHI Sustainability Summit means for the industry.